Semaglutide in India: Mechanism, Uses, Safety Profile

This is a semaglutide India clinical reference: mechanism, approved indications, the real adverse-event profile from peer-reviewed data, known interactions, and what a hospital pharmacy needs to know about supply and cost. It is not a dosing guide.

What is semaglutide and how does it work?

Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a hormone the gut releases after eating. It binds GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres.

The combined effect lowers blood glucose in type 2 diabetes and reduces caloric intake in obesity management, distinguishing it from older diabetes drugs that act primarily on insulin secretion or peripheral insulin resistance. Its long half-life allows once-weekly subcutaneous dosing for the injectable forms.

What indications does semaglutide have approval for in India?

CDSCO's Subject Expert Committee on Endocrinology and Metabolism cleared semaglutide injection for glycaemic control in type 2 diabetes, cardiovascular risk reduction and slowing chronic kidney disease progression in a July 2025 review, and separately recommended semaglutide solution across strengths from 0.25 mg to 2.4 mg for chronic weight management in adults with obesity or overweight with weight-related comorbidities in December 2025, subject to post-marketing surveillance.

Rybelsus, the oral tablet form, carries approval in India for type 2 diabetes only. It is not approved as a weight-management product, unlike the injectable Wegovy formulation, so the indication for semaglutide India prescribing depends entirely on which brand and formulation is on the chart, not the molecule name alone.

What does the real evidence say about semaglutide's side effects?

Gastrointestinal effects dominate the adverse-event profile: nausea, diarrhoea and vomiting are the most frequently reported, typically mild to moderate and concentrated in the first weeks of treatment or after a dose increase. A 2024 meta-analysis pooling trial data found nausea prevalence ranging from roughly 2% to 20% and diarrhoea from 1.4% to 13% across studies.

Pancreatitis has been the subject of specific scrutiny given the mechanism, but a systematic review and meta-analysis of semaglutide trials found no statistically significant increase in acute pancreatitis risk (odds ratio approximately 0.7, 95% CI 0.5–1.2) compared with placebo or comparator drugs, though isolated case reports continue to appear in the literature and clinicians should still maintain a low threshold for investigating unexplained abdominal pain.

Is the thyroid cancer warning on semaglutide clinically significant?

Semaglutide carries a boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, based on thyroid C-cell tumours seen in rodent studies at doses far exceeding human exposure. A systematic literature review of human data found thyroid cancer incidence in semaglutide-treated patients under 1%, with no clear signal of increased risk against comparators.

The rodent warning and the human cohort data point in different directions. That gap is precisely why the MTC/MEN2 contraindication stands regardless of the reassuring population statistics: a family history changes the calculus for one patient in a way a pooled percentage cannot.

What drug interactions matter with semaglutide?

Semaglutide slows gastric emptying, which can delay absorption of oral drugs taken alongside it, a mechanistic interaction relevant to oral contraceptives, oral antibiotics and any narrow-therapeutic-index oral medication where absorption timing matters. It also raises hypoglycaemia risk when co-prescribed with insulin or a sulfonylurea (glimepiride, gliclazide), which usually needs a dose cut at initiation per current diabetes-management guidance from ICMR.

Warfarin needs closer INR monitoring in the first weeks after starting semaglutide, since altered gastric emptying can shift anticoagulant absorption. None of this substitutes for a full interaction check against a patient's actual chart. A hospital pharmacist reviewing the medication list at dispensing catches exactly this class of interaction before it reaches the patient.

What does semaglutide India pricing and availability look like now?

The Indian patent expired on 20 March 2026, and domestic manufacturers including Dr Reddy's, Cipla and Biocon launched generic versions within weeks. Generic injectable semaglutide entered the market at roughly ₹1,290–₹4,200 per month depending on brand and pen format, against the innovator Ozempic/Wegovy range of roughly ₹8,800–₹16,400 per month that prevailed before expiry.

The WHO's Essential Medicines List Expert Committee added GLP-1 receptor agonists, including semaglutide, to its 2025 essential medicines list for diabetes with obesity comorbidity. It explicitly cited high global pricing as an access barrier, a policy stance that lines up with what generic entry has already done to the semaglutide India price since patent expiry.

Does semaglutide stocking affect a hospital's revenue and continuity of care?

A patient started on semaglutide by an endocrinology or bariatric service needs a reliable monthly refill. A weekly injectable the hospital pharmacy doesn't stock sends that prescription to an outside chemist on day one. Once the refill habit forms outside the hospital, related items tend to follow it out: test strips, co-prescribed metformin, the labs ordered alongside each refill.

Reliable in-house stocking of a high-demand molecule like semaglutide is exactly the continuity-of-care and revenue-retention problem a managed hospital pharmacy is built to solve. Our piece on prescription leakage and hospital revenue loss covers the broader pattern, and hospital pharmacy management challenges covers the operational side of keeping a fast-moving, high-cost molecule like this one in stock without tying up capital.

Sources

1. 1Gastrointestinal safety of semaglutide and tirzepatide vs. placebo: a systematic review and meta-analysis — PMC, National Institutes of Health
2. 2Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP-1RA Semaglutide: A Systematic Literature Review — PMC, National Institutes of Health
3. 3SEC Endocrinology & Metabolism recommendations, 09.12.2025 — CDSCO, Government of India
4. 4SEC Endocrinology & Metabolism recommendations, 17.07.2025 — CDSCO, Government of India
5. 5Addition of GLP-1 receptor agonists to the WHO Model List of Essential Medicines — WHO Essential Medicines List Expert Committee, 2025
6. 6National Pharmaceutical Pricing Authority — price control and DPCO scheduled formulation notifications

This article is for informational purposes for clinicians and hospital administrators and is not a substitute for professional medical advice or an individual prescribing decision. It contains no dosage instructions. Consult current CDSCO labelling and a qualified physician before any prescribing decision.